Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C8orf34 antisense RNA 1 (C8orf34-AS1)
- Target
- C8orf34-AS1
- Molecular classification
- Long non-coding RNA, Other (non-protein-coding RNA)
01
Overview
C8orf34 antisense RNA 1 (C8orf34-AS1) is a long non-coding RNA (lncRNA) transcribed in the antisense direction relative to C8orf34. It plays a regulatory role at the RNA level, notably acting as a competing endogenous RNA (ceRNA) capable of binding and sequestering microRNA-671-5p. Through this mechanism, C8orf34-AS1 upregulates the expression of MFAP4, a key gene involved in suppressing lung adenocarcinoma cell migration and stemness. The lncRNA is implicated in the modulation of tumor behavior and immune microenvironment features—such as immune cell infiltration—in cancer, particularly in lung adenocarcinoma. There are no known direct drug interactions, and its primary therapeutic interest is as a non-coding RNA biomarker or potential gene regulation target[1][3][4].
- Other names
- C8orf34-AS1C8orf34 antisense RNA 1
02
Mechanism of action
Acts as a ceRNA by sponging miR-671-5p, thereby regulating the translation of MFAP4 May regulate target mRNAs such as CDH20 and FOXI3 through lncRNA–mRNA interaction Modulates tumor cell behavior (stemness and invasion) via the C8orf34-AS1/miR-671-5p/MFAP4 axis
03
Biological functions
Competing endogenous RNA (ceRNA) activity (miRNA sponge)Regulation of gene expression (via mRNA interaction and ceRNA network)Regulation of cancer cell migration and stemness (in lung adenocarcinoma models)Modulation of immune cell infiltration and function
04
Disease associations
Cancer (with special relevance to lung adenocarcinoma)Other roles possible in cancer-related genomic instability
05
Safety considerations
None described directly; as a non-protein-coding target with regulatory roles, therapeutic modulation risks are uncharacterized
06
Biomarkers
C8orf34-AS1 expression itself is a potential biomarker for genomic instability and stemness features in lung adenocarcinomamiR-671-5p and MFAP4 levels, as components of the regulatory axis, may serve as downstream biomarkers
Beyond the preview
Go deeper on C8orf34 antisense RNA 1 (C8orf34-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C8orf34 antisense RNA 1 (C8orf34-AS1).